News
        
        Moderna Taps AWS Technology for COVID-19 Vaccine Research
        
        
        
        
Moderna announced recently that it has chosen Amazon Web   Services (AWS) to be its preferred cloud   provider, as well as its platform for running machine learning  and analytics workloads.
 While many efforts are underway to provide the first vaccine for the   deadly coronavirus, a search for "COVID-19 vaccine" shows Moderna in   most if not nearly all of the top results. Also, the firm is one of   eight companies funded by Operation Warp Speed, the public/private   partnership initiated by the federal government to hasten a vaccine. 
"Leveraging its mRNA platform and manufacturing facility with the   AWS-powered research engine, Moderna delivered the first clinical batch   of its vaccine candidate (mRNA-1273) against COVID-19 to the NIH for the   Phase 1 trial 42 days after the initial sequencing of the virus," AWS said in a release this month.
 "Moderna has invented proprietary technologies and methods that run on   AWS to create mRNA constructs that cells recognize as if they were   produced in the body," AWS said. "This invention has empowered Moderna   to experiment rapidly on virtually any mRNA sequence, easily shifting   between research priorities, without investing in new technology.   Moderna runs its Drug Design Studio on AWS's highly scalable compute and   storage infrastructure to quickly design mRNA sequences for protein   targets." 
 AWS services and technologies said to be leveraged by the biotech firm   include analytics and machine learning, the Redshift fully managed data   warehousing service, AWS IoT services and more. 
 "The science behind mRNA medicines is advancing at a rapid pace, and   building Moderna's technology platform on AWS gives our scientists the   insights, agility, and security they need to continue to lead in the   industry," AWS quoted Moderna CEO Stéphane Bancel as saying. "With AWS,   our researchers have the ability to quickly design and execute research   experiments and rapidly uncover new insights to get potentially   life-saving treatments into production faster. AWS's breadth and depth   of services are supporting our mission to create a new generation of   medicines for patients and are instrumental in our quest to develop a   vaccine for COVID-19 and other life-threatening diseases." 
        
        
        
        
        
        
        
        
        
        
        
        
            
        
        
                
                    About the Author
                    
                
                    
                    David Ramel is an editor and writer at Converge 360.